{
    "clinical_study": {
        "@rank": "55543", 
        "brief_summary": {
            "textblock": "To determine safety and tolerance of administering aerosolized recombinant interferon gamma\n      (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages\n      by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of\n      IFN-gamma can activate alveolar macrophages in AIDS patients."
        }, 
        "brief_title": "The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Diagnosis of AIDS with one or more opportunistic infections.\n\n          -  Kaposi's sarcoma with prior history of opportunistic infection.\n\n          -  Stable dose of zidovudine (AZT) therapy.\n\n          -  Preserved pulmonary, renal and hepatic function.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Presence of active infection.\n\n          -  Active opportunistic infections.\n\n          -  Cardiac disease.\n\n          -  Central nervous system disorders.\n\n          -  History of seizures.\n\n          -  Irreversible airway disease.\n\n        Patients with the following are excluded:\n\n          -  Co-existing conditions and symptoms listed in Patient Exclusion Co-existing\n             Conditions.\n\n        Prior Medication:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Immunosuppressive therapy.\n\n          -  Cytotoxic therapy.\n\n          -  Excluded:\n\n          -  Interferon gamma therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "12", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002433", 
            "org_study_id": "062A", 
            "secondary_id": "IFNG-8901"
        }, 
        "intervention": {
            "intervention_name": "Interferon gamma-1b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "Pulmonary Alveoli", 
            "Macrophage Activation", 
            "Interferon-gamma, Recombinant", 
            "Injections, Subcutaneous", 
            "Aerosols", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "New York Hosp - Cornell Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002433"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1999"
    }, 
    "geocoordinates": {
        "New York Hosp - Cornell Med Ctr": "40.714 -74.006"
    }
}